SEC Tracker
Get the app

GLAUKOS GKOS

GLAUKOS Q1 FY24: revenue $85.6M; diluted EPS −$0.82

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Key figures from this report

These are the numbers GLAUKOS reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$85.6MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$40.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.82No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$42.5MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$33.9MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when GLAUKOS files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Merit Medical Systems MMSI public float $5.4B, Jun 30, 2025
  2. MSA Safety MSA public float $6.5B, Jun 30, 2025
  3. Globus Medical GMED public float $6.6B, Jun 30, 2025
  4. iRhythm Holdings IRTC public float $4.9B, Jun 30, 2025
  5. TransMedics Group TMDX public float $4.4B, Jun 30, 2025